According to Senzer, a PK study conducted by Insys Therapeutics found that a 0.35 mg dose of dronabinol delivered by Senzer’s Voke inhaler achieved a similar maximum concentration as a 5.0 mg dose of Marinol oral dronabinol, with the inhaled dose reaching Cmax in 2 minutes compared to almost 2 hours for the oral dose.
Insys acquired US rights to the Voke inhaler for delivery of dronabinol and cannabidiol products in 2015. In April 2018, Insys announced that it was ready to begin the clinical program for the dronabinol inhaler.
Senzer CEO Alex Hearn commented, “These positive results generated by Insys show how our device can deliver cannabinoids faster and in much smaller doses, which should be of great benefit for both patients and health professionals. Our approach is unique in this exciting sector, and offers a simple and minimally invasive way to ensure much more effective delivery of pharmaceutical-grade cannabinoids.”
Insys Senior VP of Regulatory Affairs Steve Sherman said, “This pharmacokinetic study provides evidence of our unique drug-device combination’s viability as a mechanism to deliver dronabinol into the distal lung for rapid systemic absorption. Its completion represents the next step in our clinical development program for dronabinol inhalation as an investigational product concept, which has future potential in the treatment of a variety of conditions, including anorexia in cancer.”
Read the Senzer press release.
